Effects of intravenous immunoglobulin on alpha synuclein aggregation and neurotoxicity

Polymeropoulos, 1997, Mutation in the alpha-synuclein gene identified in families with Parkinson's disease, Science, 276, 2045, 10.1126/science.276.5321.2045 Gasser, 2005, Genetics of Parkinson's disease, Curr Opin Neurol, 18, 363, 10.1097/01.wco.0000170951.08924.3d Eriksen, 2005, Gene dosage and pathogenesis of Parkinson's disease, Trends Mol Med, 11, 91, 10.1016/j.molmed.2005.01.001 Winkler, 2007, alpha-Synuclein and Parkinson disease susceptibility, Neurology, 69, 1745, 10.1212/01.wnl.0000275524.15125.f4 Chartier-Harlin, 2004, Alpha-synuclein locus duplication as a cause of familial Parkinson's disease, Lancet, 364, 1167, 10.1016/S0140-6736(04)17103-1 Chiba-Falek, 2006, Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients, Mov Disord, 21, 1703, 10.1002/mds.21007 Gründemann, 2011, UV-laser microdissection and mRNA expression analysis of individual neurons from postmortem Parkinson's disease brains, Methods Mol Biol, 755, 363, 10.1007/978-1-61779-163-5_30 Conway, 2000, Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy, Proc Natl Acad Sci U S A, 97, 571, 10.1073/pnas.97.2.571 Haass, 2007, Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide, Nat Rev Mol Cell Biol, 8, 101, 10.1038/nrm2101 Winner, 2011, In vivo demonstration that alpha-synuclein oligomers are toxic, Proc Natl Acad Sci U S A, 108, 4194, 10.1073/pnas.1100976108 Halliday, 2008, Human-based studies on alpha-synuclein deposition and relationship to Parkinson's disease symptoms, Exp Neurol, 209, 12, 10.1016/j.expneurol.2007.07.006 Sidhu, 2004, The role of alpha-synuclein in both neuroprotection and neurodegeneration, Ann N Y Acad Sci, 1035, 250, 10.1196/annals.1332.016 El-Agnaf, 2004, A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders, FASEB J, 18, 1315, 10.1096/fj.03-1346fje Amer, 2006, Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders, Exp Brain Res, 173, 223, 10.1007/s00221-006-0539-y Beyer, 2008, The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies, Curr Med Chem, 15, 2748, 10.2174/092986708786242868 Caruana, 2011, Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds, FEBS Lett, 585, 1113, 10.1016/j.febslet.2011.03.046 Zhang, 2005, Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease, FASEB J, 19, 533, 10.1096/fj.04-2751com Couch, 2001, The acute inflammatory response to intranigral α-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation, J Neuroinflammation, 8, 166, 10.1186/1742-2094-8-166 Klegeris, 2007, Complement activation by islet amyloid polypeptide (IAPP) and alpha-synuclein 112, Biochem Biophys Res Commun, 357, 1096, 10.1016/j.bbrc.2007.04.055 El-Agnaf, 2003, Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma, FASEB J, 17, 1945, 10.1096/fj.03-0098fje Lee, 2008, Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease, J Mol Neurosci, 34, 17, 10.1007/s12031-007-0012-9 El-Agnaf, 2006, Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease, FASEB J, 20, 419, 10.1096/fj.03-1449com Tokuda, 2010, Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease, Neurology, 75, 1766, 10.1212/WNL.0b013e3181fd613b Bruggink, 2010, Detection of elevated levels of {alpha}-synuclein oligomers in CSF from patients with Parkinson disease, Neurology, 77, 510, 10.1212/WNL.0b013e318219dd92 Mollenhauer, 2011, α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study, Lancet Neurol, 10, 230, 10.1016/S1474-4422(11)70014-X Aerts, 2012, CSF α-synuclein does not differentiate between parkinsonian disorders, Neurobiol Aging, 33, 430, 10.1016/j.neurobiolaging.2010.12.001 Parnetti, 2011, Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias, Mov Disord, 26, 1428, 10.1002/mds.23670 Li, 2008, Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation, Nat Med, 14, 501, 10.1038/nm1746 Desplats, 2009, Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein, Proc Natl Acad Sci U S A, 106, 13010, 10.1073/pnas.0903691106 Kordower, 2011, Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat, Neurobiol Dis, 43, 552, 10.1016/j.nbd.2011.05.001 Krammer, 2009, Prion-like propagation of cytosolic protein aggregates: insights from cell culture models, Prion, 3, 206, 10.4161/pri.3.4.10013 Masliah, 2005, Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease, Neuron, 46, 857, 10.1016/j.neuron.2005.05.010 Masliah, 2011, Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease, PLoS One, 6, e19338, 10.1371/journal.pone.0019338 Patrias, 2010, Specific antibodies to soluble alpha-synuclein conformations in intravenous immunoglobulin preparations, Clin Exp Immunol, 161, 527, 10.1111/j.1365-2249.2010.04214.x Scheinfeld Nimmerjahn, 2008, Anti-inflammatory actions of intravenous immunoglobulin, Annu Rev Immunol, 26, 513, 10.1146/annurev.immunol.26.021607.090232 Dodel, 2004, Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease, J Neurol Neurosurg Psychiatry, 75, 1472, 10.1136/jnnp.2003.033399 Relkin, 2009, 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease, Neurobiol Aging, 30, 1728, 10.1016/j.neurobiolaging.2007.12.021 Shankle, 2009, Longitudinal measure of IVIG treatment effect in patients with Alzheimer's and Lewy body disease, Alzheimers Dement, 5, 430, 10.1016/j.jalz.2009.04.968 Nanri, 2009, Intravenous immunoglobulin therapy for autoantibody-positive cerebellar ataxia, Intern Med, 48, 783, 10.2169/internalmedicine.48.1802 Zouali, 1986, Thymine and guanine base specificity of human myeloma proteins with anti-DNA activity, J Clin Invest, 78, 1173, 10.1172/JCI112699 Kuby, 1992, Immunology, 100 Diemel, 2005, Characterization of immunoglobulin G fragments in liquid intravenous immunoglobulin products, Transfusion, 45, 1601, 10.1111/j.1537-2995.2005.00549.x Klaver, 2010, Antibody levels to Aβ1–42 conformations differ between intravenous immunoglobulins, Int Immunopharmacol, 10, 115, 10.1016/j.intimp.2009.10.005 Biere, 2000, Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs, J Biol Chem, 275, 34574, 10.1074/jbc.M005514200 Serpell, 2000, Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation, Proc Natl Acad Sci U S A, 97, 4897, 10.1073/pnas.97.9.4897 Uversky, 2002, Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins, J Biol Chem, 277, 11970, 10.1074/jbc.M109541200 Yonetani, 2009, Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant, J Biol Chem, 284, 7940, 10.1074/jbc.M807482200 LeVine, 1993, Thioflavine T, interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution, Protein Sci, 2, 404, 10.1002/pro.5560020312 Harper, 1997, Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins, Annu Rev Biochem, 66, 385, 10.1146/annurev.biochem.66.1.385 Giasson, 2001, A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly, J Biol Chem, 276, 2380, 10.1074/jbc.M008919200 Näsström, 2011, Antibodies against alpha-synuclein reduce oligomerization in living cells, PLoS One, 6, e27230, 10.1371/journal.pone.0027230 van Rooijen, 2010, Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease, Curr Protein Pept Sci, 11, 334, 10.2174/138920310791330659 Reynolds, 2011, Mechanism of membrane interaction and disruption by α-synuclein, J Am Chem Soc, 133, 19366, 10.1021/ja2029848 Liu, 2011, A novel molecular mechanism for nitrated {alpha}-synuclein-induced cell death, J Mol Cell Biol, 3, 239, 10.1093/jmcb/mjr011 Vassilev, 1999, Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg), Blood, 93, 3624, 10.1182/blood.V93.11.3624 Arredondo, 2005, Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in Pemphigus, Am J Pathol, 167, 1531, 10.1016/S0002-9440(10)61239-4 Leytin, 2006, Intravenous immunoglobulin inhibits anti-glycoprotein IIb-induced platelet apoptosis in a murine model of immune thrombocytopenia, Br J Haematol, 133, 78 Winkler, 2012, Platelet apoptosis in paediatric immune thrombocytopenia is ameliorated by intravenous immunoglobulin, Br J Haematol, 156, 508, 10.1111/j.1365-2141.2011.08973.x Nakatani, 2002, Intravenous immunoglobulin (IVIG) preparations induce apoptosis in TNF-alpha-stimulated endothelial cells via a mitochondria-dependent pathway, Clin Exp Immunol, 127, 445, 10.1046/j.1365-2249.2002.01769.x Takeshita, 2005, Intravenous immunoglobulin preparations promote apoptosis in lipopolysaccharide-stimulated neutrophils via an oxygen-dependent pathway in vitro, APMIS, 113, 269, 10.1111/j.1600-0463.2005.apm_05.x Haussermann, 2001, Integrity of the blood–cerebrospinal fluid barrier in early Parkinson's disease, Neurosci Lett, 300, 182, 10.1016/S0304-3940(01)01574-9 DeMattos, 2001, Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease, Proc Natl Acad Sci USA, 98, 8850, 10.1073/pnas.151261398